Director at NeuroSense (NASDAQ: NRSN) discloses equity awards and vesting
Rhea-AI Filing Summary
NeuroSense Therapeutics Ltd. director Golan Roy filed an initial Form 3 reporting his beneficial ownership of Ordinary Shares. This filing establishes his starting equity position as an insider of the company.
Footnotes indicate that certain restricted shares were granted under NeuroSense’s 2018 Share Incentive Plan and are held through a trustee to qualify for Israeli Section 102 tax benefits. These restricted shares are scheduled to vest on December 30, 2026 and January 30, 2027, subject to his continued service, with potential accelerated vesting if a specified business milestone described in his restricted share agreements is achieved.
Positive
- None.
Negative
- None.
Insider Trade Summary
3 transactions reported
Mixed
3 txns
Insider
Golan Roy
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Ordinary Shares | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
Holdings After Transaction:
Ordinary Shares — 160,844 shares (Direct)
Footnotes (3)
- F1. To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee or director in connection with the Issuer's 2018 Share Incentive Plan must be registered in the name of a trustee.
- F2. These restricted shares vest on December 30, 2026, subject to the Reporting Person's continued service to the Issuer as of such vesting date, provided that, the vesting of these restricted shares will accelerate, and the shares will become fully vested and exercisable, upon and subject to the achievement of a certain business milestone as set forth in the restricted share agreement between the Issuer and the Reporting Person.
- F3. These restricted shares vest on January 30, 2027, subject to the Reporting Person's continued service to the Issuer as of such vesting date, provided that, the vesting of these restricted shares will accelerate, and the shares will become fully vested and exercisable, upon and subject to the achievement of a certain business milestone as set forth in the restricted share agreement between the Issuer and the Reporting Person.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What does Golan Roy’s Form 3 filing for NeuroSense (NRSN) show?
The Form 3 shows that director Golan Roy has an initial beneficial ownership position in NeuroSense Ordinary Shares. It also discloses that part of his equity consists of restricted shares granted under the 2018 Share Incentive Plan with future vesting dates.
Who is the reporting person on NeuroSense (NRSN) this Form 3?
The reporting person is Golan Roy, identified as a director of NeuroSense Therapeutics Ltd. The filing records his status as a company insider and outlines his equity interests, including restricted shares subject to vesting and potential accelerated vesting conditions.
What type of securities does Golan Roy report holding in NeuroSense (NRSN)?
Golan Roy reports beneficial ownership of Ordinary Shares of NeuroSense Therapeutics Ltd. Some of these are restricted shares issued under the company’s 2018 Share Incentive Plan, subject to trustee holding arrangements and specific vesting schedules and milestones.